A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer

Cynthia X. Ma, Jingqin Luo, Michael Naughton, Foluso Ademuyiwa, Rama Suresh, Malachi Griffith, Obi L. Griffith, Zachary L. Skidmore, Nicholas C. Spies, Avinash Ramu, Lee Trani, Timothy Pluard, Gayathri Nagaraj, Shana Thomas, Zhanfang Guo, Jeremy Hoog, Jing Han, Elaine Mardis, Albert Lockhart, Matthew J. Ellis

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Purpose: This trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive (ER+) breast cancer. Experimental Design: Phase IA employed a 3+3 design to determine the MTD of buparlisib daily plus fulvestrant. Subsequent cohorts (phase IB and cohort C) evaluated intermittent (5/7-day) and continuous dosing of buparlisib (100 mg daily). No more than 3 prior systemic treatments in the metastatic setting were allowed in these subsequent cohorts. Results: Thirty-one patients were enrolled. MTD was defined as buparlisib 100 mg daily plus fulvestrant. Common adverse events (AE) included fatigue (38.7%), transaminases elevation (35.5%), rash (29%), and diarrhea (19.4%). C-peptide was significantly increased during treatment, consistent with on-target effect of buparlisib. Compared with intermittent dosing, daily buparlisib was associated with more frequent early onset AEs and higher buparlisib plasma concentrations. Among the 29 evaluable patients, the clinical benefit rate was 58.6% (95% CI, 40.7%- 74.5%). Response was not associated with PIK3CA mutation or treatment cohort; however, loss of PTEN, progesterone receptor (PgR) expression, or mutation in TP53 was most common in resistant cases, and mutations in AKT1 and ESR1 did not exclude treatment response. Conclusions: Buparlisib plus fulvestrant is clinically active with manageable AEs in patients with metastatic ER+ breast cancer. Weekend breaks in buparlisib dosing reduced toxicity. Patients with PgR negative and TP53 mutation did poorly, suggesting buparlisib plus fulvestrant may not be adequately effective against tumors with these poor prognostic molecular features.

Original languageEnglish (US)
Pages (from-to)1583-1591
Number of pages9
JournalClinical Cancer Research
Volume22
Issue number7
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Estrogen Receptors
Breast Neoplasms
Maximum Tolerated Dose
Mutation
Progesterone Receptors
fulvestrant
NVP-BKM120
C-Peptide
Therapeutics
Transaminases
Exanthema
Phosphatidylinositol 3-Kinases
Fatigue
Diarrhea
Research Design

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer. / Ma, Cynthia X.; Luo, Jingqin; Naughton, Michael; Ademuyiwa, Foluso; Suresh, Rama; Griffith, Malachi; Griffith, Obi L.; Skidmore, Zachary L.; Spies, Nicholas C.; Ramu, Avinash; Trani, Lee; Pluard, Timothy; Nagaraj, Gayathri; Thomas, Shana; Guo, Zhanfang; Hoog, Jeremy; Han, Jing; Mardis, Elaine; Lockhart, Albert; Ellis, Matthew J.

In: Clinical Cancer Research, Vol. 22, No. 7, 01.04.2016, p. 1583-1591.

Research output: Contribution to journalArticle

Ma, CX, Luo, J, Naughton, M, Ademuyiwa, F, Suresh, R, Griffith, M, Griffith, OL, Skidmore, ZL, Spies, NC, Ramu, A, Trani, L, Pluard, T, Nagaraj, G, Thomas, S, Guo, Z, Hoog, J, Han, J, Mardis, E, Lockhart, A & Ellis, MJ 2016, 'A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer', Clinical Cancer Research, vol. 22, no. 7, pp. 1583-1591. https://doi.org/10.1158/1078-0432.CCR-15-1745
Ma, Cynthia X. ; Luo, Jingqin ; Naughton, Michael ; Ademuyiwa, Foluso ; Suresh, Rama ; Griffith, Malachi ; Griffith, Obi L. ; Skidmore, Zachary L. ; Spies, Nicholas C. ; Ramu, Avinash ; Trani, Lee ; Pluard, Timothy ; Nagaraj, Gayathri ; Thomas, Shana ; Guo, Zhanfang ; Hoog, Jeremy ; Han, Jing ; Mardis, Elaine ; Lockhart, Albert ; Ellis, Matthew J. / A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 7. pp. 1583-1591.
@article{0dbf70e0cea240b4a37d4dfe13bbe99a,
title = "A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer",
abstract = "Purpose: This trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive (ER+) breast cancer. Experimental Design: Phase IA employed a 3+3 design to determine the MTD of buparlisib daily plus fulvestrant. Subsequent cohorts (phase IB and cohort C) evaluated intermittent (5/7-day) and continuous dosing of buparlisib (100 mg daily). No more than 3 prior systemic treatments in the metastatic setting were allowed in these subsequent cohorts. Results: Thirty-one patients were enrolled. MTD was defined as buparlisib 100 mg daily plus fulvestrant. Common adverse events (AE) included fatigue (38.7{\%}), transaminases elevation (35.5{\%}), rash (29{\%}), and diarrhea (19.4{\%}). C-peptide was significantly increased during treatment, consistent with on-target effect of buparlisib. Compared with intermittent dosing, daily buparlisib was associated with more frequent early onset AEs and higher buparlisib plasma concentrations. Among the 29 evaluable patients, the clinical benefit rate was 58.6{\%} (95{\%} CI, 40.7{\%}- 74.5{\%}). Response was not associated with PIK3CA mutation or treatment cohort; however, loss of PTEN, progesterone receptor (PgR) expression, or mutation in TP53 was most common in resistant cases, and mutations in AKT1 and ESR1 did not exclude treatment response. Conclusions: Buparlisib plus fulvestrant is clinically active with manageable AEs in patients with metastatic ER+ breast cancer. Weekend breaks in buparlisib dosing reduced toxicity. Patients with PgR negative and TP53 mutation did poorly, suggesting buparlisib plus fulvestrant may not be adequately effective against tumors with these poor prognostic molecular features.",
author = "Ma, {Cynthia X.} and Jingqin Luo and Michael Naughton and Foluso Ademuyiwa and Rama Suresh and Malachi Griffith and Griffith, {Obi L.} and Skidmore, {Zachary L.} and Spies, {Nicholas C.} and Avinash Ramu and Lee Trani and Timothy Pluard and Gayathri Nagaraj and Shana Thomas and Zhanfang Guo and Jeremy Hoog and Jing Han and Elaine Mardis and Albert Lockhart and Ellis, {Matthew J.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1158/1078-0432.CCR-15-1745",
language = "English (US)",
volume = "22",
pages = "1583--1591",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer

AU - Ma, Cynthia X.

AU - Luo, Jingqin

AU - Naughton, Michael

AU - Ademuyiwa, Foluso

AU - Suresh, Rama

AU - Griffith, Malachi

AU - Griffith, Obi L.

AU - Skidmore, Zachary L.

AU - Spies, Nicholas C.

AU - Ramu, Avinash

AU - Trani, Lee

AU - Pluard, Timothy

AU - Nagaraj, Gayathri

AU - Thomas, Shana

AU - Guo, Zhanfang

AU - Hoog, Jeremy

AU - Han, Jing

AU - Mardis, Elaine

AU - Lockhart, Albert

AU - Ellis, Matthew J.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose: This trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive (ER+) breast cancer. Experimental Design: Phase IA employed a 3+3 design to determine the MTD of buparlisib daily plus fulvestrant. Subsequent cohorts (phase IB and cohort C) evaluated intermittent (5/7-day) and continuous dosing of buparlisib (100 mg daily). No more than 3 prior systemic treatments in the metastatic setting were allowed in these subsequent cohorts. Results: Thirty-one patients were enrolled. MTD was defined as buparlisib 100 mg daily plus fulvestrant. Common adverse events (AE) included fatigue (38.7%), transaminases elevation (35.5%), rash (29%), and diarrhea (19.4%). C-peptide was significantly increased during treatment, consistent with on-target effect of buparlisib. Compared with intermittent dosing, daily buparlisib was associated with more frequent early onset AEs and higher buparlisib plasma concentrations. Among the 29 evaluable patients, the clinical benefit rate was 58.6% (95% CI, 40.7%- 74.5%). Response was not associated with PIK3CA mutation or treatment cohort; however, loss of PTEN, progesterone receptor (PgR) expression, or mutation in TP53 was most common in resistant cases, and mutations in AKT1 and ESR1 did not exclude treatment response. Conclusions: Buparlisib plus fulvestrant is clinically active with manageable AEs in patients with metastatic ER+ breast cancer. Weekend breaks in buparlisib dosing reduced toxicity. Patients with PgR negative and TP53 mutation did poorly, suggesting buparlisib plus fulvestrant may not be adequately effective against tumors with these poor prognostic molecular features.

AB - Purpose: This trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive (ER+) breast cancer. Experimental Design: Phase IA employed a 3+3 design to determine the MTD of buparlisib daily plus fulvestrant. Subsequent cohorts (phase IB and cohort C) evaluated intermittent (5/7-day) and continuous dosing of buparlisib (100 mg daily). No more than 3 prior systemic treatments in the metastatic setting were allowed in these subsequent cohorts. Results: Thirty-one patients were enrolled. MTD was defined as buparlisib 100 mg daily plus fulvestrant. Common adverse events (AE) included fatigue (38.7%), transaminases elevation (35.5%), rash (29%), and diarrhea (19.4%). C-peptide was significantly increased during treatment, consistent with on-target effect of buparlisib. Compared with intermittent dosing, daily buparlisib was associated with more frequent early onset AEs and higher buparlisib plasma concentrations. Among the 29 evaluable patients, the clinical benefit rate was 58.6% (95% CI, 40.7%- 74.5%). Response was not associated with PIK3CA mutation or treatment cohort; however, loss of PTEN, progesterone receptor (PgR) expression, or mutation in TP53 was most common in resistant cases, and mutations in AKT1 and ESR1 did not exclude treatment response. Conclusions: Buparlisib plus fulvestrant is clinically active with manageable AEs in patients with metastatic ER+ breast cancer. Weekend breaks in buparlisib dosing reduced toxicity. Patients with PgR negative and TP53 mutation did poorly, suggesting buparlisib plus fulvestrant may not be adequately effective against tumors with these poor prognostic molecular features.

UR - http://www.scopus.com/inward/record.url?scp=84964318224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964318224&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-1745

DO - 10.1158/1078-0432.CCR-15-1745

M3 - Article

VL - 22

SP - 1583

EP - 1591

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -